Delivery Order SPE2DB22D2206-SPE2DB25FJY48
- Not listed
- The Defense Logistics Agency awarded a $2,294.40 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Rhophylac 300 mcg/2 mL syringes. This contract represents a firm fixed-price delivery order with an ultimate completion date of October 6, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was competitively awarded without set-aside designation, reflecting AmerisourceBergen's continued capability to fulfill federal...
- The Defense Logistics Agency awarded a $1,434.00 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for Rhophylac 300 mcg/2 mL syringes, with an ultimate completion date of September 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $2,868.00 delivery order to AmerisourceBergen Drug Corp for Rhophylac 300 mcg/2 ml syringes on September 17, 2025, with an ultimate completion date of October 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Rhophylac is an immunoglobulin product used for passive immunization purposes, typically administered in...
- The Defense Logistics Agency awarded a delivery order valued at $1,147.20 to AmerisourceBergen Drug Corp for Rhophylac 300 mcg/2 mL syringes on August 29, 2025, with an ultimate completion date of September 22, 2025. This firm fixed price, non-set-aside contract represents a straightforward pharmaceutical procurement executed through AmerisourceBergen's existing indefinite delivery vehicle with DLA. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Rhophylac 300 mcg/2 mL syringes. The contract carries a ceiling value of $1,434.00 and is scheduled for completion by September 29, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award falls under...
- The Defense Logistics Agency awarded a $1,434.00 delivery order to AmerisourceBergen Drug Corp for Rhophylac 300 MCG/2 ML syringes on September 17, 2025, with an ultimate completion date of October 8, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The delivery is to be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $1,434.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Rhophylac 300 MCG/2 ML syringes on July 22, 2025, with an ultimate completion date of August 12, 2025. This non-set-aside delivery order represents a pediatric immunoglobulin product sourced through AmerisourceBergen's extensive federal pharmaceutical supply network. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $3,824.00 delivery order by the Defense Logistics Agency on September 11, 2025, for the supply of Rhophylac 300 micrograms per 2 milliliter syringes. This is a competitively awarded, non-set-aside contract utilizing firm fixed pricing, with an ultimate completion date of October 2, 2025. The award represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with...
- This delivery order, valued at $4,302.00, awards AmerisourceBergen Drug Corp the supply of Rhophylac 300 MCG/2 ML syringes under a competitively awarded, firm fixed-price contract with the Defense Logistics Agency's Medical Supply Chain. The award was issued on September 15, 2025, with an ultimate completion date of October 6, 2025. Rhophylac is an immunoglobulin product used for prevention of hemolytic disease in newborns and other clinical applications. The contract does not utilize a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Rhophylac 300 mcg/2 mL syringes, with a ceiling value of $10,755.00. The contract, awarded on July 25, 2025, carries a firm fixed price structure with an ultimate completion date of August 15, 2025. This delivery order does not utilize a set-aside designation and represents a competitive award to the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania....
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJY48Delivery Order
The Defense Logistics Agency awarded a $1,147.20 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Rhophylac 300 mcg/2 mL syringes. This competitively awarded, firm fixed-price contract is scheduled for completion by October 7, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a child order under a larger contract vehicle. This delivery order is issued under AmerisourceBergen Drug Corp's significant Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp supplies a comprehensive portfolio of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The Rhophylac product—an immunoglobulin used for passive immunization—reflects the company's role in providing specialized pharmaceutical commodities across multiple therapeutic domains to the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/16/25 |